Among all these CDKs, we focused on CDK9, as kinase inhibitors against this protein have been used to develop novel proteolysis-targeting chimeras (PROTACs), and no assessment of antitumoral activity in breast cancer has been performed with this family of agents [14,21]. This evidence concerns the gene CDK9 and breast carcinoma.